세계 수막염균 백신 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently released a detailed report on the global meningococcal vaccines market. This report provides an in-depth evaluation of critical market dynamics, including drivers, trends, opportunities, and challenges, offering a thorough understanding of the market structure.

Key Insights:

• Meningococcal Vaccines Market Size (2024E): USD 4322.73 Million
• Projected Market Value (2031F): USD 7692.59 Million
• Global Market Growth Rate (CAGR 2024 to 2031): 8.6%

Meningococcal Vaccines Market - Report Scope:

The meningococcal vaccines market is crucial for preventing infections caused by Neisseria meningitidis, including meningitis, meningococcemia, and septicemia. This market includes vaccines targeting various serogroups of the bacteria, with A, B, C, Y, and W-135 being the most common. The growing incidence of meningococcal disease, combined with increasing awareness and improved accessibility to vaccines, is driving the market's expansion.

Market Growth Drivers:

The global meningococcal vaccines market is driven by several key factors, including the increased incidence of meningococcal disease. Meningococcal meningitis, in particular, is highly contagious and can lead to severe complications or death if left untreated. The rising number of cases and the high mortality and morbidity rates associated with the disease are fueling the demand for vaccines. Additionally, increased awareness campaigns by governments, companies, and non-profit organizations are contributing to higher vaccination rates. These initiatives focus on educating the public and healthcare professionals about the importance of early detection and prevention through vaccination, thereby boosting the market. Another significant driver is the improved accessibility of meningococcal vaccines in underserved regions. Global organizations are working to make vaccines available in low-income countries, particularly in Africa, where the disease burden is high. These efforts, combined with companies' interest in entering these markets, are expected to support market growth.

Market Restraints:

Despite the promising growth prospects, the meningococcal vaccines market faces several challenges. One of the primary restraints is the limited supply of vaccines and the reliance on a few manufacturers. This issue is compounded by financial constraints in many countries, which limit their ability to procure vaccines, and by public unawareness, which reduces vaccination rates. Moreover, differential pricing strategies in developing countries can further restrict access to newly approved vaccines, limiting market penetration and growth potential.

Market Opportunities:

The meningococcal vaccines market presents substantial growth opportunities driven by ongoing efforts to increase vaccine coverage in underserved regions. Companies that successfully navigate the challenges of limited supply and pricing disparities can capitalize on the growing demand in these markets. Furthermore, continued investment in public awareness campaigns and partnerships with global health organizations are likely to enhance market growth.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the meningococcal vaccines market globally?
• Which serogroups of meningococcal bacteria are most commonly targeted by vaccines?
• How are global health initiatives influencing the competitive landscape of the meningococcal vaccines market?
• Who are the key players in the meningococcal vaccines market, and what strategies are they employing to enhance their market presence?
• What are the emerging trends and future prospects in the global meningococcal vaccines market?

Competitive Intelligence and Business Strategy:

Leading players in the global meningococcal vaccines market, including companies such as GlaxoSmithKline, Pfizer, Sanofi Pasteur, and Merck & Co., focus on innovation, strategic partnerships, and expanding their reach into underserved markets to gain a competitive edge. These companies invest in research and development to offer vaccines that target multiple serogroups and improve vaccine efficacy and accessibility. Collaborations with global health organizations and governments help to enhance vaccine distribution and coverage, particularly in low-income regions. Emphasis on public education and awareness campaigns drives market growth and strengthens market positioning in the dynamic meningococcal vaccines industry.

Key Companies Profiled:

• Sanofi Pasteur Inc.
• GlaxoSmithKline
• Wyeth Pharmaceuticals

Meningococcal Vaccines Market Categorization

Meningococcal Vaccines Market by Product

• Polysaccharide Vaccine
• Conjugate Vaccine
• Serogroup B Vaccine

Meningococcal Vaccines Market by Age Group

• Infants (0-24 months)
• Children
• Adolescents and Young Adults
• Adults

Meningococcal Vaccines Market by Distribution Channel

• Institutional Sales
• Retail Sales

Meningococcal Vaccines Market by Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation

4. Key Success Factors

• 4.1. Pipeline Analysis
• 4.2. Recent Product Launches
• 4.3. Promotional Strategies, by Manufacturers
• 4.4. Regulatory Scenario

5. Global Meningococcal Vaccine Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

• 5.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 5.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
  • 5.2.1. Y-o-Y Growth Trend Analysis
  • 5.2.2. Absolute $ Opportunity Analysis

6. Market Background

• 6.1. Macro-Economic Factors
  • 6.1.1. Global Healthcare Spending Outlook
  • 6.1.2. Global Pharmaceutical Outlook
  • 6.1.3. Regional Healthcare Market Outlook
• 6.2. Forecast Factors - Relevance & Impact
• 6.3. Value Chain
• 6.4. Pipeline Analysis
• 6.5. Market Dynamics
  • 6.5.1. Drivers
  • 6.5.2. Restraints
  • 6.5.3. Opportunity Analysis

7. Global Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, by Product Type

• 7.1. Introduction / Key Findings
• 7.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2019-2023
• 7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2024-2031
  • 7.3.1. Meningococcal Polysaccharide Vaccine (MPSV4)
  • 7.3.2. Meningococcal Conjugate Vaccine (MCV4)
  • 7.3.3. Serogroup B Meningococcal Vaccine (MenB-FHpb/MenB-4C)
• 7.4. Market Attractiveness Analysis By Product Type

8. Global Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, by Age Group

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Age Group, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Age Group, 2024-2031
  • 8.3.1. Infants (0-24 months)
  • 8.3.2. Children
  • 8.3.3. Adolescents and Young Adults
  • 8.3.4. Adults
• 8.4. Market Attractiveness Analysis By Age Group

9. Global Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, by Distribution Channel

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2031
  • 9.3.1. Institutional Sales
    • 9.3.1.1. Hospitals
    • 9.3.1.2. Community Clinics
    • 9.3.1.3. Public Health Agencies
  • 9.3.2. Retail Sales
    • 9.3.2.1. Retail Pharmacy
    • 9.3.2.2. Mail Order Pharmacy
• 9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, by Region

• 10.1. Introduction
• 10.2. Historical Market Size (US$ Mn) and Volume Analysis By Region, 2019-2023
• 10.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast By Region, 2024-2031
  • 10.3.1. North America
  • 10.3.2. Latin America
  • 10.3.3. Europe
  • 10.3.4. East Asia
  • 10.3.5. South Asia
  • 10.3.6. Oceania
  • 10.3.7. Middle East and Africa (MEA)
• 10.4. Market Attractiveness Analysis By Region

11. North America Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
• 11.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
  • 11.3.1. By Country
    • 11.3.1.1. U.S.
    • 11.3.1.2. Canada
  • 11.3.2. By Product Type
  • 11.3.3. By Age Group
  • 11.3.4. By Distribution Channel
• 11.4. Market Attractiveness Analysis
• 11.5. Market Trends
• 11.6. Key Market Participants - Intensity Mapping
• 11.7. Drivers and Restraints - Impact Analysis

12. Latin America Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
• 12.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
  • 12.3.1. By Country
    • 12.3.1.1. Brazil
    • 12.3.1.2. Mexico
    • 12.3.1.3. Rest of Latin America
  • 12.3.2. By Product Type
  • 12.3.3. By Age Group
  • 12.3.4. By Distribution Channel
• 12.4. Market Attractiveness Analysis
• 12.5. Market Trends
• 12.6. Key Market Participants - Intensity Mapping
• 12.7. Drivers and Restraints - Impact Analysis

13. Europe Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
• 13.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
  • 13.3.1. By Country
    • 13.3.1.1. Germany
    • 13.3.1.2. Italy
    • 13.3.1.3. France
    • 13.3.1.4. U.K.
    • 13.3.1.5. Spain
    • 13.3.1.6. BENELUX
    • 13.3.1.7. Russia
    • 13.3.1.8. Rest of Europe
  • 13.3.2. By Product Type
  • 13.3.3. By Age Group
  • 13.3.4. By Distribution Channel
• 13.4. Market Attractiveness Analysis
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis

14. South Asia Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

• 14.1. Introduction
• 14.2. Pricing Analysis
• 14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
• 14.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
  • 14.4.1. By Country
    • 14.4.1.1. India
    • 14.4.1.2. Thailand
    • 14.4.1.3. Indonesia
    • 14.4.1.4. Malaysia
    • 14.4.1.5. Rest of South Asia
  • 14.4.2. By Product Type
  • 14.4.3. By Age Group
  • 14.4.4. By Distribution Channel
• 14.5. Market Attractiveness Analysis
• 14.6. Market Trends
• 14.7. Key Market Participants - Intensity Mapping
• 14.8. Drivers and Restraints - Impact Analysis

15. East Asia Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
• 15.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
  • 15.3.1. By Country
    • 15.3.1.1. China
    • 15.3.1.2. Japan
    • 15.3.1.3. South Korea
  • 15.3.2. By Product Type
  • 15.3.3. By Age Group
  • 15.3.4. By Distribution Channel
• 15.4. Market Attractiveness Analysis
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis

16. Oceania Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
• 16.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
  • 16.3.1. By Country
    • 16.3.1.1. Australia
    • 16.3.1.2. New Zealand
  • 16.3.2. By Product Type
  • 16.3.3. By Age Group
  • 16.3.4. By Distribution Channel
• 16.4. Market Attractiveness Analysis
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
• 17.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
  • 17.3.1. By Country
    • 17.3.1.1. GCC Countries
    • 17.3.1.2. Turkey
    • 17.3.1.3. Northern Africa
    • 17.3.1.4. South Africa
    • 17.3.1.5. Rest of Middle East and Africa
  • 17.3.2. By Product Type
  • 17.3.3. By Age Group
  • 17.3.4. By Distribution Channel
• 17.4. Market Attractiveness Analysis
• 17.5. Market Trends
• 17.6. Key Market Participants - Intensity Mapping
• 17.7. Drivers and Restraints - Impact Analysis

18. Emerging Countries Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

• 18.1. Introduction
  • 18.1.1. Market Value Proportion Analysis, By Key Countries
  • 18.1.2. Global Vs. Country Growth Comparison
• 18.2. China Meningococcal Vaccine Market Analysis
  • 18.2.1. Introduction
  • 18.2.2. PEST Analysis
  • 18.2.3. Market Value Proportion Analysis by Market Taxonomy
  • 18.2.4. Market Volume (Mn Units) and Value (US$ Mn) Analysis and Forecast by Market Taxonomy
    • 18.2.4.1. By Product Type
    • 18.2.4.2. By Age Group
    • 18.2.4.3. By Distribution Channel
• 18.3. India Meningococcal Vaccine Market Analysis
  • 18.3.1. Introduction
  • 18.3.2. PEST Analysis
  • 18.3.3. Market Value Proportion Analysis by Market Taxonomy
  • 18.3.4. Market Volume (Mn Units) and Value (US$ Mn) Analysis and Forecast by Market Taxonomy
    • 18.3.4.1. By Product Type
    • 18.3.4.2. By Age Group
    • 18.3.4.3. By Distribution Channel
• 18.4. Brazil Meningococcal Vaccine Market Analysis
  • 18.4.1. Introduction
  • 18.4.2. PEST Analysis
  • 18.4.3. Market Value Proportion Analysis by Market Taxonomy
  • 18.4.4. Market Volume (Mn Units) and Value (US$ Mn) Analysis and Forecast by Market Taxonomy
    • 18.4.4.1. By Product Type
    • 18.4.4.2. By Age Group
    • 18.4.4.3. By Distribution Channel

19. Market Structure Analysis

• 19.1. Market Analysis by Tier of Companies (Meningococcal Vaccine)
• 19.2. Market Share Analysis of Top Players
• 19.3. Brand Share Analysis
• 19.4. Market Presence Analysis
  • 19.4.1. By Regional footprint of Players
  • 19.4.2. Product foot print by Players
  • 19.4.3. Channel Foot Print by Players

20. Competition Analysis

• 20.1. Competition Dashboard
• 20.2. Pricing Analysis by Competition
• 20.3. Competition Benchmarking
• 20.4. Competition Deep Dive
  • 20.4.1. Sanofi Pasteur Inc.
    • 20.4.1.1. Overview
    • 20.4.1.2. Product Portfolio
    • 20.4.1.3. Profitability by Market Segments (Product/Channel/Region)
    • 20.4.1.4. Sales Footprint
    • 20.4.1.5. Strategy Overview
      • 20.4.1.5.1. Marketing Strategy
      • 20.4.1.5.2. Product Strategy
      • 20.4.1.5.3. Channel Strategy
  • 20.4.2. GlaxoSmithKline
    • 20.4.2.1. Overview
    • 20.4.2.2. Product Portfolio
    • 20.4.2.3. Profitability by Market Segments (Product/Channel/Region)
    • 20.4.2.4. Sales Footprint
    • 20.4.2.5. Strategy Overview
      • 20.4.2.5.1. Marketing Strategy
      • 20.4.2.5.2. Product Strategy
      • 20.4.2.5.3. Channel Strategy
  • 20.4.3. Wyeth Pharmaceuticals
    • 20.4.3.1. Overview
    • 20.4.3.2. Product Portfolio
    • 20.4.3.3. Profitability by Market Segments (Product/Channel/Region)
    • 20.4.3.4. Sales Footprint
    • 20.4.3.5. Strategy Overview
      • 20.4.3.5.1. Marketing Strategy
      • 20.4.3.5.2. Product Strategy
      • 20.4.3.5.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology